Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 6/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639742 | 0.84 | CDK4 (0.67) | KDM4EHIF1AHTTALDH1A1HPGD | |
| SCHEMBL19405224 | 0.84 | CDK4 (0.67) | KDM4EHIF1AHTTALDH1A1HPGD | |
| SCHEMBL11672350 | 0.83 | MAPK1 (0.62) | MAPK1KDM4ETDP1HIF1AHTT | |
| SCHEMBL188449 | 0.83 | HIF1A (0.65) | TDP1HIF1AHTTALDH1A1HPGD | |
| SCHEMBL258823 | 0.82 | HIF1A (0.75) | HIF1AHTTALDH1A1HPGDCDK4 | |
| Hydrochloric Acid SCHEMBL5396629 | 0.81 | HIF1A (0.68) | HIF1AHTTALDH1A1HPGDCDK4 | |
| Hydrochloric Acid SCHEMBL5257349 | 0.81 | HIF1A (0.68) | HIF1AHTTALDH1A1HPGDCDK4 | |
| SCHEMBL1496558 | 0.80 | MAPT (0.57) | MAPK1KDM4ETDP1HTTALDH1A1 | |
| SCHEMBL1496758 | 0.80 | MAPK1 (0.62) | MAPK1KDM4ETDP1HTTALDH1A1 | |
| SCHEMBL12663754 | 0.80 | MAPK1 (0.62) | MAPK1KDM4ETDP1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261331-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | US | disclosed |
| EP-1539757-A1 | SUBSTITUTED PYRROLOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016609-A1 | SUBSTITUTED PYRROLOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261331-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | MAPK1 117/4885KDM4E 1691/4885TDP1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.